> GENR – Are you familiar with exponential growth? Could dosing also follow the same curve for some drugs?<
There appears to be some dose response in the 10-40mg range; the question is whether there is any dose response in the 40-160mg range.
To date, the only trial that tested a dose higher than 40mg was the phase-1/2 study from Mexico (the one which generated the slides in #msg-1605364), and that study showed no dose response between the doses equivalent to 40mg and 80mg.
Hence, there is no evidence to date that Evizon has a dose response in the 40-80mg range, and there is some evidence that it does not. 160mg hasn’t yet been tested in any AMD trial, but it will be tested in the planned phase-2 trial known as “212.”
Of course, all this will be immaterial if GENR continues to have trouble enrolling patients into its phase-3 trial(s). Regards, Dew
Market Data 
Markets 
AI
